Pfizer and Valneva’s Lyme Disease Vaccine Shows Promising, Though Complex, Phase 3 Results
(Archynews) – In a significant development for Lyme disease prevention, Pfizer and Valneva have announced topline results from the Phase 3 VALOR trial of their investigational Lyme disease vaccine, PF-07307405 (LB6V, formerly VLA15). The results, released on March 23, 2026, present a nuanced picture, with the vaccine demonstrating effectiveness but falling short of the primary endpoint in initial analysis.
Understanding Lyme Disease and the Need for a Vaccine
Lyme disease, spread through the bite of infected ticks, is the most prevalent vector-borne disease in the United States and Europe. According to Valneva, approximately 476,000 cases are recorded annually in the U.S. And 132,000 in Europe. Initial symptoms often include a characteristic rash, fatigue, fever, and headaches, but if left untreated, the infection can lead to severe complications affecting the joints, heart, and nervous system.
The VALOR Trial and Initial Findings
The VALOR trial, sponsored by Pfizer, is a multicenter, placebo-controlled, randomized, observer-blinded study conducted across the U.S., Canada, and Europe. The trial evaluated the efficacy, safety, and immunogenicity of the 6-valent OspA-based Lyme disease vaccine candidate. Participants completed a primary vaccination series of three doses, followed by a booster approximately one year later.
The primary endpoint of the trial required an efficacy of at least 20% in reducing confirmed Lyme disease cases with a 95% confidence interval. An initial analysis showed an efficacy rate of 15.8% 28 days after the fourth dose, missing the primary endpoint.
A Second Analysis Offers Hope
Although, a subsequent predefined analysis revealed a more encouraging result: an efficacy of 21.7% with a 95% confidence interval on the first day following administration of the fourth dose. Despite not meeting the primary endpoint, Pfizer has decided to proceed with submitting authorization files to regulatory authorities, citing the “clinically significant effectiveness observed.”
Partnership and Future Outlook
The development of this Lyme disease vaccine is a collaborative effort between Pfizer and Valneva. Pfizer is responsible for the final stages of development and commercialization, although Valneva receives payments from Pfizer. Pfizer anticipates potential commercialization of the vaccine in the second half of 2027.
The Phase 3 trial results have caused a significant drop in Valneva’s stock price, but the decision to move forward with regulatory submissions suggests continued confidence in the vaccine’s potential. Further updates will be crucial as the vaccine progresses through the approval process.
Related reading